Why I’m Still Bullish on Novo Nordisk After the Recent Sell-Off
Novo Nordisk has been sold off aggressively after a string of negative headlines: an underperforming CagriSema trial, a 50% list-price cut announcement and renewed competitive pressure from Eli Lilly. Those shocks are real, but the company’s market position in diabetes and obesity, a $165.8B market cap, a sub-11x P/E and a 3.27% dividend yield crea…